Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 am ET. This event will be available via webcast on their Investors & Media page, with a replay accessible for 90 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating severe diseases, including various cancers and inflammatory conditions. Their pipeline highlights antibody-based therapeutics that engage the human immune system to enhance patient outcomes.

News Market Reaction – CLDX

+0.70%

+0.70% Session move

In the trading session that priced this news, CLDX gained 0.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Conference today at 9:20 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com

FAQ

When will Celldex Therapeutics participate in the SVB Securities Global Biopharma Conference?

Celldex Therapeutics will participate in the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 am ET.

How can I watch the Celldex Therapeutics fireside chat?

The fireside chat can be watched via webcast on the Investors & Media section of the Celldex website.

How long will the recording of the Celldex conference presentation be available?

A replay of the presentation will be available for 90 days following the event.

What is the focus of Celldex Therapeutics' product development?

Celldex Therapeutics develops monoclonal and bispecific antibodies targeting severe diseases with inadequate treatments, including various cancers and inflammatory diseases.